{
    "url_original": "https://www.wsj.com/articles/gileads-revenue-declines-on-waning-sales-of-covid-19-drug-11643756250?mod=business_lead_pos6",
    "url": "gileads-revenue-declines-on-waning-sales-of-covid-19-drug-11643756250",
    "title": "Gilead’s Revenue Declines on Waning Sales of Covid-19 Drug",
    "sub_head": "Decrease in revenue for remdesivir comes amid falling pandemic hospitalizations",
    "category_1": "Business",
    "category_2": "Earnings",
    "image_1_url": "https://images.wsj.net/im-478187?width=860&height=573",
    "image_1": "im-478187.jpg",
    "time": "2022-02-01 17:57:00",
    "body": "Gilead Sciences Inc.’s  revenue fell in the fourth quarter, as sales of its Covid-19 treatment remdesivir waned amid greater vaccine availability and declining hospitalization numbers.<br />The biopharmaceutical company posted $7.24 billion in revenue for the quarter, above analysts’ expectations of $6.62 billion. Gilead reported $7.42 billion in revenue for the same period last year."
}